Capricor Therapeutics Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for CAPR, updated each market day.
CAPR AI Sentiment
AI predicts Capricor Therapeutics Inc stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Sector
Exchange
Market Cap
$1,817,911,172
Cap Tier
Employees
231
Headquarters
SAN DIEGO, CA
Listed Since
June 20, 2002
Website
CAPR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CAPR Volatility
Capricor Therapeutics Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
